HCCA’s 2020 Boston Regional Healthcare Compliance Conference

Foley Partner Lawrence Vernaglia, member of the firm’s Health Care Industry Team, as well as Foley Partner Mike Crossen, member of the firm’s Government Solutions Practice Group, and Mike Capuano, Director of the firm’s Public Affairs Practice Group, will be speaking at the HCCA 2020 Boston Regional Healthcare Compliance Conference.

Lawrence will be part of the “Covid-19 Compliance Panel Discussion” at 11:00 a.m. CT with Jim Bryant (Brigham Health), Beth Gutoff (Elliot Health System), and Rick King (UMass Memorial Medical Center). The panel will share their experiences as it relates to the COVID-19 pandemic with regard to key compliance risks, impacts to compliance programs, and post-pandemic planning.

Mike Capuano and Mike Crossen are co-hosting the “Reading the Tea Leaves: Projecting Change in the Healthcare Industry Relating to the 2020 Presidential Election” panel at 3:30 p.m. CT, and will focus on key health policy issues on the platforms of each candidate, predictions for what changes hospitals and other providers could expect following January 2021 inauguration, and what should a compliance officer be thinking about for project out the next 18 months.

To find out more, or register for the virtual conference, click here.

lvernaglia@foley.com

Boston 617.342.4079

mcrossen@foley.com

Washington, D.C. 202.295.4440

Related Insights

View All Posts

June 3, 2025 Foley Corporate Governance Update

Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders

On June 2, 2025, the Texas Legislature passed Senate Bill 2337, meaningfully regulating proxy advisors like ISS and Glass Lewis when providing proxy voting recommendations concerning Texas companies.

September 25, 2025 Events

Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners 

June 3, 2025 Health Care Law Today

GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for metabolic disorders, particularly type 2 diabetes and obesity.

HCCA’s 2020 Boston Regional Healthcare Compliance Conference

People

Lawrence W. Vernaglia

Michael K. Crossen

Related Insights

Texas Senate Bill 2337: Protecting Texas Companies and Their Directors, Shareholders and Boards from Proxy Advice Not in the Financial Interests of Shareholders

Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners

GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health

Unclaimed Property Roundtable with Delaware State Escheator and Leading Practitioners 